The pleiotropic role of the fibrinogen γ′ chain in hemostasis

Blood

Volumn 114, Issue 19, 2009, Pages 3994-4001

  De Willige, Shirley Uitte ^a   Standeven, Kristina F ^a   Philippou, Helen ^a   Ariëns, Robert A S ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13; FIBRINOGEN; FIBRINOGEN GAMMA; HETERODIMER; THROMBIN; UNCLASSIFIED DRUG;

ARTERY THROMBOSIS; BLOOD CLOT; CARBOXY TERMINAL SEQUENCE; HEMOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; VEIN THROMBOSIS;

EID: 77950380887     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-05-217968     Document Type: Review

References (101)

1. Weisel JW. Fibrinogen and fibrin. Adv Protein Chem. 2005;70:247-299.
2. Doolittle RF. Searching for differences between fibrinogen and fibrin that affect the initiation of fibrinolysis. Cardiovasc Hematol Agents Med Chem. 2008;6(3):181-189.
3. Kant JA, Fornace AJ Jr, Saxe D, et al. Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci U S A. 1985;82(8):2344-2348.
4. Chung DW, Davie EW. Gamma and γ′ chains of human fibrinogen are produced by alternative mRNA processing. Biochemistry. 1984;23(18):4232- 4236.
5. Francis CW, Marder VJ, Martin SE. Demonstration of a large molecular weight variant of the gamma chain of normal human plasma fibrinogen. J Biol Chem. 1980;255(12):5599-5604.
6. Fornace AJ Jr, Cummings DE, Comeau CM, Kant JA, Crabtree GR. Structure of the human gamma-fibrinogen gene: alternate mRNA splicing near the 3′ end of the gene produces gamma A and gamma B forms of gamma-fibrinogen. J Biol Chem. 1984;259(20):12826-12830.
7. Peerschke EI, Francis CW, Marder VJ. Fibrinogen binding to human blood platelets: effect of gamma chain carboxyterminal structure and length. Blood. 1986;67(2):385-390.
8. Wolfenstein-Todel C, Mosesson MW. Human plasma fibrinogen heterogeneity: evidence for an extended carboxyl-terminal sequence in a normal gamma chain variant (γ′). Proc Natl Acad Sci U S A. 1980;77(9):5069-5073.
9. Doolittle RF, Hong S, Wilcox D. Evolution of the fibrinogen γ′ chain: implications for the binding of factor XIII, thrombin and platelets. J Thromb Haemost. 2009;7;1431-1433.
10. Mosesson MW, Finlayson JS. Subfractions of human fibrinogen; preparation and analysis. J Lab Clin Med. 1963;62:663-674.
11. Mosesson MW, Finlayson JS, Umfleet RA. Human fibrinogen heterogeneities: 3. Identification of chain variants. J Biol Chem. 1972;247(16):5223-5227.
12. Meh DA, Siebenlist KR, Mosesson MW. Identification and characterization of the thrombin binding sites on fibrin. J Biol Chem. 1996;271(38):23121-23125.
13. Francis CW, Kraus DH, Marder VJ. Structural and chromatographic heterogeneity of normal plasma fibrinogen associated with the presence of three gamma-chain types with distinct molecular weights. Biochim Biophys Acta. 1983;744(2):155-164.
14. Francis CW, Keele EM, Marder VJ. Purification of three gamma-chains with different molecular weights from normal human plasma fibrinogen. Biochim Biophys Acta. 1984;797(3):328-335.
15. Francis CW, Muller E, Henschen A, Simpson PJ, Marder VJ. Carboxyl-terminal amino acid sequences of two variant forms of the gamma chain of human plasma fibrinogen. Proc Natl Acad Sci U S A. 1988;85(10):3358-3362.
16. Haidaris PJ, Francis CW, Sporn LA, et al. Megakaryocyte and hepatocyte origins of human fibrinogen biosynthesis exhibit hepatocytespecific expression of gamma chain-variant polypeptides. Blood. 1989;74(2):743-750.
17. Haidaris PJ, Courtney MA. Tissue-specific and ubiquitous expression of fibrinogen gamma-chain mRNA. Blood Coagul Fibrinolysis. 1990;1(4):433-437.
18. Haidaris PJ, Peerschke EI, Marder VJ, Francis CW. The C-terminal sequences of the gamma 57.5 chain of human fibrinogen constitute a plasmin sensitive epitope that is exposed in crosslinked fibrin. Blood. 1989;74(7):2437-2444.
19. Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood. 2005;106:2605-2612.
20. Lovely RS, Moaddel M, Farrell DH. Fibrinogen γ′ chain binds thrombin exosite II. J Thromb Haemost. 2003;1(1):124-131.
21. Pospisil CH, Stafford AR, Fredenburgh JC, Weitz JI. Evidence that both exosites on thrombin participate in its high affinity interaction with fibrin. J Biol Chem. 2003;278(24):21584-21591.
22. Meh DA, Siebenlist KR, Brennan SO, Holyst T, Mosesson MW. The amino acid sequence in fibrin responsible for high affinity thrombin binding. Thromb Haemost. 2001;85(3):470-474.
23. de Bosch NB, Mosesson MW, Ruiz-Saez A, Echenagucia M, Rodriguez-Lemoin A. Inhibition of thrombin generation in plasma by fibrin formation (antithrombin I). Thromb Haemost. 2002;88(2):253-258.
24. Sabo TM, Farrell DH, Maurer MC. Conformational analysis of γ′ peptide (410-427) interactions with thrombin anion binding exosite II. Biochemistry. 2006;45(24):7434-7445.
25. Pineda AO, Chen ZW, Marino F, et al. Crystal structure of thrombin in complex with fibrinogen γ′ peptide. Biophys Chem. 2007;125(2):556-559.
26. Seegers WH, Nieft M, Loomis EC. Note on the adsorption of thrombin on fibrin. Science. 1945;101(2629):520-521.
27. Seegers WH. Multiple protein interactions as exhibited by the blood-clotting mechanism. J Phys Colloid Chem. 1947;51:198-206.
28. Mosesson MW. Antithrombin I: inhibition of thrombin generation in plasma by fibrin formation. Thromb Haemost. 2003;89(1):9-12.
29. Mosesson MW. Update on antithrombin I (fibrin). Thromb Haemost. 2007;98(1):105-108.
30. Siebenlist KR, Mosesson MW, Hernandez I, et al. Studies on the basis for the properties of fibrin produced from fibrinogen containing γ′ chains. Blood. 2005;106(8):2730-2736.
31. Lovely RS, Boshkov LK, Marzec UM, Hanson SR, Farrell DH. Fibrinogen γ′ chain carboxy terminal peptide selectively inhibits the intrinsic coagulation pathway. Br J Haematol. 2007;139(3):494-503.
32. Fredenburgh JC, Stafford AR, Leslie BA, Weitz JI. Bivalent binding to gammaA/gamma′-fibrin engages both exosites of thrombin and protects it from inhibition by the antithrombin-heparin complex. J Biol Chem. 2008;283(5):2470-2477.
33. Cooper AV, Standeven KF, Ariëns RA. Fibrinogen gamma-chain splice variant γ′ alters fibrin formation and structure. Blood. 2003;102(2):535-540.
34. Pospisil CH, Stafford AR, Fredenburgh JC, Weitz JI. gA/g′ fibrin affords thrombin greater protection from inhibition by the heparin/antithrombin complex than gA/gA fibrin [abstract]. J Thromb Haemost. 2003;1(suppl 1):Abstract OC372.
35. Carter WJ, Cama E, Huntington JA. Crystal structure of thrombin bound to heparin. J Biol Chem. 2005;280(4):2745-2749.
36. Becker DL, Fredenburgh JC, Stafford AR, Weitz JI. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. J Biol Chem. 1999;274(10):6226-6233.
37. Philippou H, Rance J, Myles T, et al. Roles of low specificity and cofactor interaction sites on thrombin during factor XIII activation: competition for cofactor sites on thrombin determines its fate. J Biol Chem. 2003;278(34):32020-32026.
38. Mosesson MW, Cooley BC, Hernandez I, DiOrio JP, Weiler H. Thrombosis risk modification in transgenic mice containing the human fibrinogen thrombin-binding γ′ chain sequence. J Thromb Haemost. 2009;7(1):102-110.
39. Hawiger J, Timmons S, Kloczewiak M, Strong DD, Doolittle RF. γ and α chains of human fibrinogen possess sites reactive with human platelet receptors. Proc Natl Acad Sci U S A. 1982;79(6): 2068-2071.
40. Kloczewiak M, Timmons S, Hawiger J. Localization of a site interacting with human platelet receptor on carboxy-terminal segment of human fibrinogen gamma chain. Biochem Biophys Res Commun. 1982;107(1):181-187.
41. Kloczewiak M, Timmons S, Hawiger J. Recognition site for the platelet receptor is present on the 15-residue carboxy-terminal fragment of the gamma chain of human fibrinogen and is not involved in the fibrin polymerization reaction. Thromb Res. 1983;29(2):249-255.
42. Kloczewiak M, Timmons S, Lukas TJ, Hawiger J. Platelet receptor recognition site on human fibrinogen: synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain. Biochemistry. 1984;23(8):1767-1774.
43. Harfenist EJ, Packham MA, Mustard JF. Effects of variant gamma chains and sialic acid content of fibrinogen upon its interactions with ADPstimulated human and rabbit platelets. Blood. 1984;64(6):1163-1168.
44. Peerschke EI, Francis CW, Marder VJ. Fibrinogen binding to human blood platelets: effect of gamma chain carboxyterminal structure and length. Blood. 1986;67(2):385-390.
45. Hettasch JM, Bolyard MG, Lord ST. The residues AGDV of recombinant gamma chains of human fibrinogen must be carboxy-terminal to support human platelet aggregation. Thromb Haemost. 1992;68(6):701-706.
46. Farrell DH, Thiagarajan P. Binding of recombinant fibrinogen mutants to platelets. J Biol Chem. 1994;269(1):226-231.
47. Lancellotti S, Rutella S, De Filippis V, et al. The fibrinogen elongated gamma-chain inhibits thrombin-induced platelet response, hindering the interaction with different receptors. J Biol Chem. 2008;283(44):30193-30204.
48. Lovely RS, Rein CM, White TC, et al. γA/γ′ fibrinogen inhibits thrombin-induced platelet aggregation. Thromb Haemost. 2008;100(5):837-846.
49. Kieffer N, Guichard J, Farcet JP, Vainchenker W, Breton-Gorius J. Biosynthesis of major platelet proteins in human blood platelets. Eur J Biochem. 1987;164(1):189-195.
50. Weyrich AS, Schwertz H, Kraiss LW, Zimmerman GA. Protein synthesis by platelets: historical and new perspectives. J Thromb Haemost. 2009;7(2):241-246.
51. Francis CW, Nachman RL, Marder VJ. Plasma and platelet fibrinogen differ in gamma chain content. Thromb Haemost. 1984;51(1):84-88.
52. Mosesson MW, Homandberg GA, Amrani DL. Human platelet fibrinogen gamma chain structure. Blood. 1984;63(5):990-995.
53. Denis MM, Tolley ND, Bunting M, et al. Escaping the nuclear confines: signal-dependent premRNA splicing in anucleate platelets. Cell. 2005;122(3):379-391.
54. Schwertz H, Tolley ND, Foulks JM, et al. Signaldependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets. J Exp Med. 2006;203(11):2433-2440.
55. Lorand L. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann N Y Acad Sci. 2001;936:291-311.
56. Mosesson MW, Finlayson JS. Biochemical and chromatographic studies of certain activities associated with human fibrinogen preparations. J Clin Invest. 1963;42:747-755.
57. Lorand L. Fibrinoligase: the fibrin-stabilizing factor system of blood plasma. Ann N Y Acad Sci. 1972;202:6-30.
58. Gaffney PJ, Whitaker AN. Fibrin crosslinks and lysis rates. Thromb Res. 1979;14(1):85-94.
59. Siebenlist KR, Mosesson MW. Progressive crosslinking of fibrin gamma chains increases resistance to fibrinolysis. J Biol Chem. 1994;269(45):28414- 28419.
60. Siebenlist KR, Meh DA, Mosesson MW. Plasma factor XIII binds specifically to fibrinogen molecules containing gamma chains. Biochemistry. 1996;35(32):10448-10453.
61. Moaddel M, Farrell DH, Daugherty MA, Fried MG. Interactions of human fibrinogens with factor XIII: roles of calcium and the γ′ peptide. Biochemistry. 2000;39(22):6698-6705.
62. Nagy B Jr, Simon Z, Bagoly Z, Muszbek L, Kappelmayer J. Binding of plasma factor XIII to thrombin-receptor activated human platelets. Thromb Haemost. 2009;102(1):83-89.
63. Gersh KC, Lord ST. An investigation of Factor XIII binding to recombinant g′/g′ and gA/g′ fibrinogen. Blood. 2006;108(11):1705.
64. Janus TJ, Lewis SD, Lorand L, Shafer JA. Promotion of thrombin-catalyzed activation of factor XIII by fibrinogen. Biochemistry. 1983;22(26):6269-6272.
65. Greenberg CS, Achyuthan KE, Fenton JW. Factor XIIIa formation promoted by complexing of alphathrombin, fibrin, and plasma factor XIII. Blood. 1987;69(3):867-871.
66. Naski MC, Lorand L, Shafer JA. Characterization of the kinetic pathway for fibrin promotion of alpha-thrombin-catalyzed activation of plasma factor XIII. Biochemistry. 1991;30(4):934-941.
67. Moaddel M, Falls LA, Farrell DH. The role of gamma A/gamma′ fibrinogen in plasma factor XIII activation. J Biol Chem. 2000;275(41):32135- 32140.
68. Siebenlist KR, Meh DA, Mosesson MW. Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin. Thromb Haemost. 2001;86(5):1221-1228.
69. Falls LA, Farrell DH. Resistance of gammaA/γ′ fibrin clots to fibrinolysis. J Biol Chem. 1997;272(22):14251-14256.
70. Collet JP, Nagaswami C, Farrell DH, Montalescot G, Weisel JW. Influence of γ′ fibrinogen splice variant on fibrin physical properties and fibrinolysis rate. Arterioscler Thromb Vasc Biol. 2004;24(2):382-386.
71. Collet JP, Woodhead JL, Soria J, et al. Fibrinogen Dusart: electron microscopy of molecules, fibers and clots, and viscoelastic properties of clots. Biophys J. 1996;70(1):500-510.
72. Marchi R, Mirshahi SS, Soria C, et al. Thrombotic dysfibrinogenemia: fibrinogen "Caracas V" relation between very tight fibrin network and defective clot degradability. Thromb Res. 2000;99(2):187-193.
73. Lefebvre P, Velasco PT, Dear A, et al. Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen AalphaIVS4 + 1G>T mutation and an AalphaGln328 truncation (fibrinogen Keokuk). Blood. 2004;103(7):2571-2576.
74. Fatah K, Hamsten A, Blomback B, Blomback M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost. 1992;68(2):130-135.
75. Fatah K, Silveira A, Tornvall P, et al. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost. 1996;76(4):535-540.
76. Gersh KC, Nagaswami C, Weisel JW, Lord ST. The presence of γ′ chain impairs fibrin polymerization. Thromb Res. 2009;124(3):356-363.
77. Weisel JW, Nagaswami C. Computer modeling of fibrin polymerization kinetics correlated with electron microscope and turbidity observations: clot structure and assembly are kinetically controlled. Biophys J. 1992;63(1):111-128.
78. Farrell DH. Fibrinogen containing γ′ chains. Blood. 2006;107(7):3011-3012.
79. Siebenlist KR. Fibrinogen containing γ′ chains: is the assay measuring what Farrel's group expects? Blood. 2006;107(7):3012.
80. Drouet L, Paolucci F, Pasqualini N, et al. Plasma γ′/γ fibrinogen ratio, a marker of arterial thrombotic activity: a new potential cardiovascular risk factor? Blood Coagul Fibrinolysis. 1999;10(suppl 1):S35-S39.
81. Uitte de Willige S, de Visser MCH, Houwing-Duistermaat JJ, et al. Genetic variation in the fibrinogen gamma gene increases the risk of deep venous thrombosis by reducing plasma fibrinogen γ′ levels. Blood. 2005;106(13):4176-4183.
82. Mosesson MW, Hernandez I, Raife TJ, et al. Plasma fibrinogen gamma prime chain content in the thrombotic microangiopathy syndrome. J Thromb Haemost. 2007;5(1):62-69.
83. Lovely RS, Falls LA, Al Mondhiry HA, et al. Association of gammaA/γ′ fibrinogen levels and coronary artery disease. Thromb Haemost. 2002;88(1):26-31.
84. Mannila MN, Lovely RS, Kazmierczak SC, et al. Elevated plasma fibrinogen γ′ concentration is associated with myocardial infarction: effects of variation in fibrinogen genes and environmental factors. J Thromb Haemost. 2007;5(4):766-773.
85. Kamath S, Lip GY. Fibrinogen: biochemistry, epidemiology and determinants. QJM. 2003;96(10):711-729.
86. Pulanic D, Rudan I. The past decade: fibrinogen. Coll Antropol. 2005;29(1):341-349.
87. Cheung EY, Uitte de Willige S, Vos HL, et al. Fibrinogen γ′ in ischemic stroke: a case-control study. Stroke. 2008;39(3):1033-1035.
88. Bruggemann LW, Drijfhout JW, Reitsma PH, Spek CA. Alternatively spliced tissue factor in mice: induction by Streptococcus pneumoniae. J Thromb Haemost. 2006;4(4):918-920.
89. Xiong Z, Shaibani A, Li YP, et al. Alternative splicing factor ASF/SF2 is down regulated in inflamed muscle. J Clin Pathol. 2006;59(8):855-861.
90. Mizgerd JP, Spieker MR, Lupa MM. Exon truncation by alternative splicing of murine ICAM-1. Physiol Genomics. 2002;12(1):47-51.
91. Nowak-Göttl U, Weiler H, Hernandez I, et al. Fibrinogen alpha and gamma genes and factor V Leiden in children with thromboembolism: results from two family-based association studies. Blood. 2009;114(9):1947-1953.
92. Grünbacher G, Weger W, Marx-Neuhold E, et al. The fibrinogen gamma (FGG) 10034C>T polymorphism is associated with venous thrombosis. Thromb Res. 2007;131(1):33-36.
93. Uitte de Willige S, Pyle ME, Vos HL, et al. Fibrinogen gamma gene 3′-end polymorphisms and risk of venous thromboembolism in the African-American and Caucasian population. Thromb Haemost. 2009;101(6):1078- 1084.
94. Mannila MN, Eriksson P, Lundman P, et al. Contribution of haplotypes across the fibrinogen gene cluster to variation in risk of myocardial infarction. Thromb Haemost. 2005;93(3):570-577.
95. Uitte de Willige S, Doggen CJM, de Visser MCH, Bertina RM, Rosendaal FR. Haplotypes of the fibrinogen gamma gene do not affect the risk of myocardial infarction. J Thromb Haemost. 2006;4(2):474-476.
96. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 2000;95(5):1517-1532.
97. Simmonds RE, Hermida J, Rezende SM, Lane DA. Haemostatic genetic risk factors in arterial thrombosis. Thromb Haemost. 2001;86(1):374-385.
98. Uitte de Willige S, Rietveld IM, de Visser MC, Vos HL, Bertina RM. Polymorphism 10034C>T is located in a region regulating polyadenylation of FGG transcripts and influences the fibrinogen γ′/γA mRNA ratio. J Thromb Haemost. 2007;5(6):1243-1249.
99. Baumann RE, Henschen AH. Human fibrinogen polymorphic site analysis by restriction endonuclease digestion and allele-specific polymerase chain reaction amplification: identification of polymorphisms at positions A alpha 312 and B beta 448. Blood. 1993;82(7):2117-2124.
100. Standeven KF, Grant PJ, Carter AM, et al. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation. 2003;107(18):2326-2330.
101. Carter AM, Catto AJ, Kohler HP, et al. Alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood. 2000;96(3):1177-1179.